A randomized, double-blind, placebo-controlled, olanzapine-referenced, parallel group safety, efficacy, and tolerability study of SCA-136 [vabicaserin] in subjects with acute exacerbations of schizophrenia
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2014
At a glance
- Drugs Vabicaserin (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Wyeth
- 07 Dec 2007 Status changed from in progress to completed.
- 05 Nov 2006 New trial record.